Our pipeline

From cutting-edge science to groundbreaking therapies

Our portfolio reflects our dedication to providing impactful and transformative therapies to patients in need.

We’re diligently progressing through preclinical studies, delving into efficacy, toxicology, and safety pharmacology.

Our overarching goal? To advance to proof-of-concept clinical trials that will allow us to offer innovative solutions to the pharmaceutical market.

Product INDICATIONS Discovery Pre-Clinical Phase I Phase II Phase III
Non-Regulatory Regulatory
AIK3a-cc IL-1β-related
diseases

AIK3a-cc is our first product